Global Targeted Therapeutics Market Research Report - Industry Analysis, Size, Share, Growth, Trends and Forecast 2024 to 2032

Description

List of Tables

The global demand for Targeted Therapeutics Market is presumed to reach the market size of nearly USD 134.3 Billion by 2032 from USD 70.58 Billion in 2023 with a CAGR of 7.41% under the study period 2024 - 2032.

Targeted therapeutics is a class of medical treatments that selectively target specific molecules or pathways involved in disease processes. Unlike traditional broad-spectrum therapies, targeted therapeutics aim to deliver precise and effective treatment while minimizing adverse effects on healthy tissues. These therapies often utilize monoclonal antibodies, small molecule inhibitors, gene therapies, or immunotherapies to interfere with cancer cell growth, inhibit abnormal signaling pathways, or modulate the immune system's response.

MARKET DYNAMICS

Progress in molecular biology & genomics has allowed for a more profound comprehension of disease mechanisms at the molecular level, paving the way for developing targeted therapies that can precisely target disease-causing molecules, minimizing side effects and improving efficacy. Additionally, the increasing incidence of chronic diseases such as cancer, autoimmune disorders, and cardiovascular diseases has increased the demand for more effective and personalized treatment options, further driving the market for targeted therapeutics. Moreover, regulatory initiatives aimed at expediting the approval process for targeted drugs and increasing investments in research and development by pharmaceutical companies are contributing to the market growth. Furthermore, the rising adoption of companion diagnostics to pinpoint individuals most likely to gain from targeted therapies is enhancing market penetration. Lastly, technological advancements such as next-generation sequencing and gene editing technologies open new avenues for developing novel targeted therapeutics, fostering innovation and driving market expansion. However, regulatory challenges in drug development, high research & development costs, and competition from established treatment modalities may restrict the targeted therapeutics Market.

The research report covers Porter's Five Forces Model, Market Attractiveness Analysis, and Value Chain analysis. These tools help to get a clear picture of the industry's structure and evaluate the competition attractiveness at a global level. Additionally, these tools also give an inclusive assessment of each segment in the global market of targeted therapeutics. The growth and trends of targeted therapeutics industry provide a holistic approach to this study.

MARKET SEGMENTATION

This section of the targeted therapeutics market report provides detailed data on the segments at country and regional level, thereby assisting the strategist in identifying the target demographics for the respective product or services with the upcoming opportunities.

By Type

Monoclonal Antibodies (Angiogenesis Inhibitors, Her-2 Targeted Agents, And Anti-Cd20 Monoclonal Antibodies)
Small Molecule (Tyrosine Kinase Inhibitors)

By Application

Breast Cancer
Colorectal Cancer
Leukemia
Lung Cancer
Lymphoma
Multiple Sclerosis
Renal Cancer
Wet Age-Related Macular Degeneration
Others (Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer, And Pancreatic Cancer)

By Distribution Channel

Hospital Pharmacies
Retail Pharmacies
Online Pharmacies

REGIONAL ANALYSIS

This section covers the regional outlook, which accentuates current and future demand for the Targeted Therapeutics market across North America, Europe, Asia-Pacific, Latin America, and Middle East & Africa. Further, the report focuses on demand, estimation, and forecast for individual application segments across all the prominent regions.

The research report also covers the comprehensive profiles of the key players in the market and an in-depth view of the competitive landscape worldwide. The major players in the Targeted Therapeutics market include Sanofi, GlaxoSmithKline plc., Takeda Pharmaceutical Company Ltd., Merck & Co., Inc., Novartis AG, Pfizer Inc., F. Hoffmann-La Roche Ltd., AstraZeneca, Seagen, Inc., Bayer AG, Amgen, Inc., Bristol-Myers Squibb Company. This section consists of a holistic view of the competitive landscape that includes various strategic developments such as key mergers & acquisitions, future capacities, partnerships, financial overviews, collaborations, new product developments, new product launches, and other developments.

In case you have any custom requirements, do write to us. Our research team can offer a customized report as per your need.

Product Code: VMR112114054

1 . PREFACE

1.1. Report Description
- 1.1.1. Objective
- 1.1.2. Target Audience
- 1.1.3. Unique Selling Proposition (USP) & offerings
1.2. Research Scope
1.3. Research Methodology
- 1.3.1. Market Research Process
- 1.3.2. Market Research Methodology

2 . EXECUTIVE SUMMARY

2.1. Highlights of Market
2.2. Global Market Snapshot

3 . TARGETED THERAPEUTICS - INDUSTRY ANALYSIS

3.1. Introduction - Market Dynamics
3.2. Market Drivers
3.3. Market Restraints
3.4. Opportunities
3.5. Industry Trends
3.6. Porter's Five Force Analysis
3.7. Market Attractiveness Analysis
- 3.7.1 Market Attractiveness Analysis By Type
- 3.7.2 Market Attractiveness Analysis By Application
- 3.7.3 Market Attractiveness Analysis By Distribution Channel
- 3.7.4 Market Attractiveness Analysis By Region

4 . VALUE CHAIN ANALYSIS

4.1. Value Chain Analysis
4.2. Raw Material Analysis
- 4.2.1. List of Raw Materials
- 4.2.2. Raw Material Manufactures List
- 4.2.3. Price Trend of Key Raw Materials
4.3. List of Potential Buyers
4.4. Marketing Channel
- 4.4.1. Direct Marketing
- 4.4.2. Indirect Marketing
- 4.4.3. Marketing Channel Development Trend

5 . GLOBAL TARGETED THERAPEUTICS MARKET ANALYSIS BY TYPE

5.1 Overview by Type
5.2 Historical and Forecast Data
5.3 Analysis by Type
5.4 Monoclonal Antibodies (Angiogenesis Inhibitors, HER-2 Targeted Agents, and Anti-CD20 Monoclonal Antibodies) Historic and Forecast Sales by Regions
5.5 Small Molecule (Tyrosine Kinase Inhibitors) Historic and Forecast Sales by Regions

6 . GLOBAL TARGETED THERAPEUTICS MARKET ANALYSIS BY APPLICATION

6.1 Overview by Application
6.2 Historical and Forecast Data
6.3 Analysis by Application
6.4 Breast Cancer Historic and Forecast Sales by Regions
6.5 Colorectal Cancer Historic and Forecast Sales by Regions
6.6 Leukemia Historic and Forecast Sales by Regions
6.7 Lung Cancer Historic and Forecast Sales by Regions
6.8 Lymphoma Historic and Forecast Sales by Regions
6.9 Multiple Sclerosis Historic and Forecast Sales by Regions
6.10. Renal Cancer Historic and Forecast Sales by Regions
6.11 Wet Age-related Macular Degeneration Historic and Forecast Sales by Regions
6.12 Others (Ovarian Cancer, Fallopian Tube Cancer, Prostate Cancer, and Pancreatic Cancer) Historic and Forecast Sales by Regions

7 . GLOBAL TARGETED THERAPEUTICS MARKET ANALYSIS BY DISTRIBUTION CHANNEL

7.1 Overview by Distribution Channel
7.2 Historical and Forecast Data
7.3 Analysis by Distribution Channel
7.4 Hospital Pharmacies Historic and Forecast Sales by Regions
7.5 Retail Pharmacies Historic and Forecast Sales by Regions
7.6 Online Pharmacies Historic and Forecast Sales by Regions

8 . GLOBAL TARGETED THERAPEUTICS MARKET ANALYSIS BY GEOGRAPHY

8.1. Regional Outlook
8.2. Introduction
8.3. North America Sales Analysis
- 8.3.1. Overview, Historic and Forecast Data Sales Analysis
- 8.3.2. North America By Segment Sales Analysis
- 8.3.3. North America By Country Sales Analysis
- 8.3.4. United State Sales Analysis
- 8.3.5. Canada Sales Analysis
- 8.3.6. Mexico Sales Analysis
8.4. Europe Sales Analysis
- 8.4.1. Overview, Historic and Forecast Data Sales Analysis
- 8.4.2. Europe by Segment Sales Analysis
- 8.4.3. Europe by Country Sales Analysis
- 8.4.4. United Kingdom Sales Analysis
- 8.4.5. France Sales Analysis
- 8.4.6. Germany Sales Analysis
- 8.4.7. Italy Sales Analysis
- 8.4.8. Russia Sales Analysis
- 8.4.9. Rest Of Europe Sales Analysis
8.5. Asia Pacific Sales Analysis
- 8.5.1. Overview, Historic and Forecast Data Sales Analysis
- 8.5.2. Asia Pacific by Segment Sales Analysis
- 8.5.3. Asia Pacific by Country Sales Analysis
- 8.5.4. China Sales Analysis
- 8.5.5. India Sales Analysis
- 8.5.6. Japan Sales Analysis
- 8.5.7. South Korea Sales Analysis
- 8.5.8. Australia Sales Analysis
- 8.5.9. South East Asia Sales Analysis
- 8.5.10. Rest Of Asia Pacific Sales Analysis
8.6. Latin America Sales Analysis
- 8.6.1. Overview, Historic and Forecast Data Sales Analysis
- 8.6.2. Latin America by Segment Sales Analysis
- 8.6.3. Latin America by Country Sales Analysis
- 8.6.4. Brazil Sales Analysis
- 8.6.5. Argentina Sales Analysis
- 8.6.6. Peru Sales Analysis
- 8.6.7. Chile Sales Analysis
- 8.6.8. Rest of Latin America Sales Analysis
8.7. Middle East & Africa Sales Analysis
- 8.7.1. Overview, Historic and Forecast Data Sales Analysis
- 8.7.2. Middle East & Africa by Segment Sales Analysis
- 8.7.3. Middle East & Africa by Country Sales Analysis
- 8.7.4. Saudi Arabia Sales Analysis
- 8.7.5. UAE Sales Analysis
- 8.7.6. Israel Sales Analysis
- 8.7.7. South Africa Sales Analysis
- 8.7.8. Rest Of Middle East And Africa Sales Analysis

9 . COMPETITIVE LANDSCAPE OF THE TARGETED THERAPEUTICS COMPANIES

9.1. Targeted Therapeutics Market Competition
9.2. Partnership/Collaboration/Agreement
9.3. Merger And Acquisitions
9.4. New Product Launch
9.5. Other Developments

10 . COMPANY PROFILES OF TARGETED THERAPEUTICS INDUSTRY

10.1. Company Share Analysis
10.2. Market Concentration Rate
10.3. Sanofi
- 10.3.1. Company Overview
- 10.3.2. Company Revenue
- 10.3.3. Products
- 10.3.4. Recent Developments
10.4. GlaxoSmithKline plc.
- 10.4.1. Company Overview
- 10.4.2. Company Revenue
- 10.4.3. Products
- 10.4.4. Recent Developments
10.5. Takeda Pharmaceutical Company Ltd.
- 10.5.1. Company Overview
- 10.5.2. Company Revenue
- 10.5.3. Products
- 10.5.4. Recent Developments
10.6. Merck & Co. Inc.
- 10.6.1. Company Overview
- 10.6.2. Company Revenue
- 10.6.3. Products
- 10.6.4. Recent Developments
10.7. Novartis AG
- 10.7.1. Company Overview
- 10.7.2. Company Revenue
- 10.7.3. Products
- 10.7.4. Recent Developments
10.8. Pfizer Inc.
- 10.8.1. Company Overview
- 10.8.2. Company Revenue
- 10.8.3. Products
- 10.8.4. Recent Developments
10.9. F. Hoffmann-La Roche Ltd.
- 10.9.1. Company Overview
- 10.9.2. Company Revenue
- 10.9.3. Products
- 10.9.4. Recent Developments
10.10. AstraZeneca
- 10.10.1. Company Overview
- 10.10.2. Company Revenue
- 10.10.3. Products
- 10.10.4. Recent Developments
10.11. Seagen Inc.
- 10.11.1. Company Overview
- 10.11.2. Company Revenue
- 10.11.3. Products
- 10.11.4. Recent Developments
10.12. Bayer AG
- 10.12.1. Company Overview
- 10.12.2. Company Revenue
- 10.12.3. Products
- 10.12.4. Recent Developments
10.13. Amgen Inc.
- 10.13.1. Company Overview
- 10.13.2. Company Revenue
- 10.13.3. Products
- 10.13.4. Recent Developments
10.14. Bristol-Myers Squibb Company
- 10.14.1. Company Overview
- 10.14.2. Company Revenue
- 10.14.3. Products
- 10.14.4. Recent Developments

Note - in company profiling, financial details and recent development are subject to availability or might not be covered in case of private companies